title: Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.
abstract: Twenty-seven patients suffering from long-standing, severe, recurrent herpes simplex (14 labial and 13 genital) who had not responded adequately to prior therapy were recruited for this open, monitored study. They were treated with thymopentin 50 mg subcutaneously three times weekly for a period of 6 weeks. Clinical controls were performed once a week and then again 6 weeks after cessation of therapy; laboratory investigations were done at time points 0, 3, and 6 weeks. Additionally, information was collected with regard to the clinical course during the following year. Thirteen of 14 patients with labial infection and 10 of the 13 with genital herpes improved markedly (p less than 0.05) as shown by decrease in the relapse rate of at least 50%, shorter relapse episodes, and improvement of symptoms such as pain and itching. Fourteen of these 27 patients experienced no relapse for a period longer than 4 months after cessation of therapy. These favorable results were paralleled by a statistically significant increase in the T cell helper/suppressor ratio. This finding indicates that thymopentin acts as an immunodomulator; it is assumed that the activation of T helper cells induces-presumable via interleukin 2-the proliferation of cytotoxic T lymphocytes and natural killer cells which play a major role in the natural immune defense. No serious side effects of thymopentin were recorded.
authors.forename: J
authors.initials: J
authors.lastname: DeMaubeuge
authors.forename: E
authors.initials: E
authors.lastname: Haneke
authors.forename: D
authors.initials: D
authors.lastname: Djawari
authors.forename: K
authors.initials: K
authors.lastname: Wolff
authors.forename: G
authors.initials: G
authors.lastname: Stingl
authors.forename: L
authors.initials: L
authors.lastname: Molin
authors.forename: E
authors.initials: E
authors.lastname: Schöpf
authors.forename: R
authors.initials: R
authors.lastname: Stengel
authors.forename: H
authors.initials: H
authors.lastname: Degreef
authors.forename: E
authors.initials: E
authors.lastname: Panconesi
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000276:immunology; D006560:Herpes Labialis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin